Phase I Clinical Trial to Evaluate the Tolerability and Safety of TQB2858 Injection in Subjects With Metastatic Pancreatic Cancer
Latest Information Update: 12 Dec 2023
At a glance
- Drugs Catequentinib (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary) ; TQB-2858 (Primary)
- Indications Carcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group; Nanjing Shunxin Pharmaceutical
Most Recent Events
- 03 Dec 2023 Status changed from recruiting to discontinued.
- 02 Nov 2022 Status changed from not yet recruiting to recruiting.
- 20 Jan 2022 New trial record